-DOCSTART-	O

Title	O
:	O
[	O
Safety	O
of	O
adjuvant	B-I
dose	I-I
-	I-I
dense	I-I
chemotherapy	I-I
with	O
paclitaxel	B-I
and	O
epirubicin	B-I
for	O
high	O
-	O
risk	O
breast	O
cancer	O
]	O
.	O

METHODS	O
:	O
From	O
January	O
2004	O
to	O
December	O
2006	O
,	O
101	B-P
patients	I-P
with	I-P
high	I-P
-	I-P
risk	I-P
breast	I-P
cancer	I-P
after	I-P
surgical	I-P
resection	I-P
were	O
enrolled	O
into	O
this	O
study	O
.	O

The	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
dose	B-I
-	I-I
dense	I-I
and	O
regular	B-C
groups	O
.	O

Each	O
patient	O
received	O
6	B-I
cycles	I-I
of	I-I
chemotherapy	I-I
with	O
intravenous	B-I
administration	I-I
of	I-I
paclitaxel	I-I
(	O
175	O
mg	O
/	O
m2	O
,	O
on	O
D3	O
)	O
and	O
epirubicin	B-I
(	O
60	O
mg	O
/	O
m2	O
,	O
on	O
Dl	O
and	O
D2	O
)	O
.	O

The	B-I
dose	I-I
-	I-I
dense	I-I
group	O
had	O
repeated	O
treatment	O
every	O
two	O
weeks	O
,	O
while	O
the	B-C
regular	I-C
group	O
repeated	O
it	O
every	O
three	O
weeks	O
.	O

G	B-I
-	I-I
CSF	I-I
was	O
used	O
in	O
a	O
dose	O
of	O
3	O
microg	O
/	O
kg	O
on	O
D5	O
-	O
D9	O
during	O
each	O
cycle	O
in	O
the	B-I
dose	I-I
-	I-I
dense	I-I
group	O
.	O

While	O
in	O
the	B-C
regular	I-C
group	O
,	O
it	O
was	O
used	O
only	O
under	O
the	O
condition	O
that	O
grade	O
II	O
neutropenia	O
occurred	O
.	O

-DOCSTART-	O

Title	O
:	O
A	B-I
randomized	I-I
breast	I-I
-	I-I
feeding	I-I
promotion	I-I
intervention	I-I
did	O
not	O
reduce	O
child	O
obesity	O
in	O
Belarus	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
17	I-P
,	I-P
046	I-P
healthy	I-P
breast	I-P
-	I-P
fed	I-P
infants	I-P
were	O
enrolled	O
from	O
31	O
Belarussian	O
maternity	O
hospitals	O
and	O
affiliated	O
clinics	O
,	O
of	O
whom	O
13	O
,	O
889	O
(	O
81	O
.	O
5	O
%	O
)	O
were	O
followed	O
up	O
at	O
6	O
.	O
5	O
y	O
with	O
duplicate	O
measurements	O
of	O
height	B-O
,	O
weight	B-O
,	O
waist	B-O
circumference	I-O
,	O
triceps	B-O
and	O
subscapular	B-O
skinfold	I-O
thicknesses	I-O
,	O
systolic	B-O
and	O
diastolic	B-O
BP	I-O
.	O

Analysis	O
was	O
based	O
on	O
intention	O
to	O
treat	O
,	O
with	O
statistical	O
adjustment	O
for	O
clustering	O
within	O
hospitals	O
/	O
clinics	O
to	O
permit	O
inferences	O
at	O
the	O
individual	O
level	O
.	O

-DOCSTART-	O

Title	O
:	O
Recommendations	O
for	O
implementing	O
stereotactic	B-I
radiotherapy	I-I
in	O
peripheral	O
stage	O
IA	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
:	O
report	O
from	O
the	O
Quality	O
Assurance	O
Working	O
Party	O
of	O
the	O
randomised	O
phase	O
III	O
ROSEL	O
study	O
.	O

METHODS	O
:	O
A	O
Quality	O
Assurance	O
Working	O
Party	O
was	O
formed	O
by	O
radiation	O
oncologists	O
and	O
clinical	O
physicists	O
from	O
both	O
academic	O
as	O
well	O
as	O
non	O
-	O
academic	O
hospitals	O
that	O
had	O
already	O
implemented	O
stereotactic	B-I
radiotherapy	I-I
for	O
lung	O
cancer	O
.	O

A	O
literature	O
survey	O
was	O
conducted	O
and	O
consensus	O
meetings	O
were	O
held	O
in	O
which	O
both	O
the	O
knowledge	O
from	O
the	O
literature	O
and	O
clinical	O
experience	O
were	O
pooled	O
.	O

In	O
addition	O
,	O
a	O
planning	O
study	O
was	O
performed	O
in	O
26	O
stage	O
I	O
patients	O
,	O
of	O
which	O
22	O
were	O
stage	O
1A	O
,	O
in	O
order	O
to	O
develop	O
and	O
evaluate	O
the	O
planning	O
guidelines	O
.	O

Plans	O
were	O
optimised	O
according	O
to	O
parameters	O
adopted	O
from	O
RTOG	O
trials	O
using	O
both	O
an	O
algorithm	O
with	O
a	O
simple	O
homogeneity	O
correction	O
(	O
Type	O
A	O
)	O
and	O
a	O
more	O
advanced	O
algorithm	O
(	O
Type	O
B	O
)	O
.	O

Dose	O
conformity	O
requirements	O
were	O
then	O
formulated	O
based	O
on	O
these	O
results	O
.	O

-DOCSTART-	O

Title	O
:	O
MF101	B-I
,	I-I
a	I-I
selective	I-I
estrogen	I-I
receptor	I-I
beta	I-I
modulator	I-I
for	O
the	O
treatment	O
of	O
menopausal	O
hot	O
flushes	O
:	O
a	O
phase	O
II	O
clinical	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
blinded	O
trial	O
in	O
217	B-P
postmenopausal	I-P
women	I-P
with	I-P
hot	I-P
flushes	I-P
randomized	O
to	O
5	B-I
or	O
10	B-I
g	I-I
/	I-I
day	I-I
of	I-I
MF101	I-I
or	O
placebo	B-C
for	O
12	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
FDA	O
review	O
of	O
a	B-I
panitumumab	I-I
(	I-I
Vectibix	I-I
)	I-I
clinical	O
trial	O
for	O
first	O
-	O
line	O
treatment	O
of	O
metastatic	O
colorectal	O
cancer	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
closed	O
when	O
inferior	B-O
PFS	I-O
and	O
greater	B-O
toxicity	I-O
were	O
demonstrated	O
at	O
the	O
time	O
of	O
the	O
planned	O
interim	O
efficacy	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Randomized	O
clinical	O
trial	O
between	O
nutritional	B-I
counselling	I-I
and	O
commercial	B-I
hypocaloric	I-I
diet	I-I
in	O
weight	O
loss	O
in	O
obese	B-P
patients	I-P
with	I-P
chronic	I-P
arthropathy	I-P
]	O
.	O

METHODS	O
:	O
Thirty	B-P
six	I-P
patients	I-P
were	O
randomized	O
in	O
both	O
branches	O
:	O
diet	O
I	O
with	O
lunch	O
and	O
dinner	O
substituted	O
by	O
two	B-I
Optisource	I-I
(	O
1109	O
,	O
3	O
kcal	O
/	O
day	O
,	O
166	O
,	O
4g	O
of	O
carbohydrates	O
(	O
60	O
%	O
)	O
,	O
63g	O
of	O
proteins	O
(	O
23	O
%	O
)	O
,	O
21	O
,	O
3g	O
of	O
lipids	O
17	O
%	O
)	O
and	O
diet	O
II	O
with	O
nutritional	B-I
counselling	I-I
with	O
a	O
decrease	O
of	O
500	O
cal	O
/	O
day	O
from	O
the	O
previous	O
dietary	O
intake	O
.	O

Before	O
and	O
3	O
months	O
after	O
treatment	O
,	O
a	B-O
nutritional	I-O
and	O
biochemical	B-O
study	I-O
was	O
performed	O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
electrofunctional	O
data	O
following	O
argon	B-I
-	I-I
laser	I-I
trabeculoplasty	I-I
in	O
primary	O
open	O
-	O
angle	O
glaucoma	O
.	O

METHODS	O
:	O
The	B-I
laser	I-I
treatment	I-I
was	O
carried	O
out	O
in	O
only	O
one	O
eye	O
chosen	O
at	O
random	O
,	O
and	O
the	B-C
fellow	I-C
eye	I-C
was	O
used	O
as	O
a	O
control	O
.	O

In	O
the	O
present	O
study	O
we	O
intended	O
to	O
verify	O
the	B-O
possibility	I-O
of	I-O
using	I-O
electrofunctional	I-O
techniques	I-O
to	O
determine	O
the	O
two	O
distinct	O
and	O
,	O
probably	O
,	O
consecutive	O
glaucomatous	O
alterations	O
occurring	O
in	O
ganglion	O
cells	O
:	O
functional	O
(	O
reversible	O
)	O
and	O
anatomical	O
(	O
irreversible	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Rapid	O
efficacy	O
of	O
the	B-I
highly	I-I
selective	I-I
alpha1A	I-I
-	I-I
adrenoceptor	I-I
antagonist	I-I
silodosin	I-I
in	O
men	B-P
with	I-P
signs	I-P
and	I-P
symptoms	I-P
of	I-P
benign	I-P
prostatic	I-P
hyperplasia	I-P
:	O
pooled	O
results	O
of	O
2	O
phase	O
3	O
studies	O
.	O

METHODS	O
:	O
Men	B-P
50	I-P
years	I-P
or	I-P
older	I-P
with	I-P
an	I-P
International	I-P
Prostate	I-P
Symptom	I-P
Score	I-P
of	I-P
13	I-P
or	I-P
greater	I-P
and	I-P
peak	I-P
urinary	I-P
flow	I-P
rate	I-P
of	I-P
4	I-P
to	I-P
15	I-P
ml	I-P
per	I-P
second	I-P
received	O
placebo	B-C
or	O
8	B-I
mg	I-I
silodosin	I-I
daily	O
with	O
breakfast	O
for	O
12	O
weeks	O
.	O

The	O
primary	O
end	O
point	O
was	O
International	B-O
Prostate	I-O
Symptom	I-O
Score	I-O
change	O
from	O
baseline	O
to	O
last	O
observation	O
.	O

Change	O
in	O
peak	B-O
urinary	I-O
flow	I-O
rate	I-O
was	O
a	O
secondary	O
end	O
point	O
.	O

Differences	O
in	O
treatment	B-O
efficacy	I-O
were	O
assessed	O
by	O
ANCOVA	O
.	O

-DOCSTART-	O

Title	O
:	O
Osteoporosis	O
and	O
gait	O
and	O
balance	O
disturbances	O
in	O
older	B-P
sarcopenic	I-P
obese	I-P
New	I-P
Zealanders	I-P
.	O

Bone	O
,	O
muscle	O
,	O
and	O
fat	O
may	O
affect	O
gait	O
and	O
balance	O
in	O
older	O
adults	O
.	O

Osteoporosis	O
was	O
prevalent	O
in	O
low	O
muscle	O
mass	O
participants	O
and	O
related	O
to	O
gait	O
and	O
balance	O
deficits	O
.	O

Low	O
muscle	O
combined	O
with	O
high	O
fat	O
mass	O
had	O
more	O
functional	O
deficits	O
and	O
poorer	O
bone	O
health	O
,	O
which	O
has	O
implications	O
for	O
falls	O
risk	O
and	O
fractures	O
.	O

METHODS	O
:	O
One	B-P
hundred	I-P
eighty	I-P
-	I-P
three	I-P
older	I-P
adults	I-P
(	I-P
age	I-P
72	I-P
.	I-P
7	I-P
+	I-P
/	I-P
-	I-P
6	I-P
years	I-P
,	I-P
range	I-P
56	I-P
-	I-P
93	I-P
;	I-P
body	I-P
mass	I-P
index	I-P
28	I-P
.	I-P
2	I-P
+	I-P
/	I-P
-	I-P
4	I-P
.	I-P
9	I-P
,	I-P
range	I-P
16	I-P
.	I-P
6	I-P
-	I-P
46	I-P
.	I-P

0	I-P
)	I-P
were	O
recruited	O
from	O
a	O
New	O
Zealand	O
falls	O
prevention	O
intervention	O
trial	O
.	O

Total	B-O
and	O
appendicular	B-O
skeletal	I-O
muscle	I-O
mass	I-O
(	I-O
ASM	I-O
)	I-O
,	O
percent	B-O
fat	I-O
,	O
and	O
bone	B-O
mineralization	I-O
were	O
assessed	O
by	O
dual	B-O
energy	I-O
X	I-O
-	I-O
ray	I-O
absorptiometry	I-O
and	O
used	O
to	O
characterize	O
normal	B-I
lean	I-I
(	O
NL	B-I
,	O
n	O
=	O
51	O
)	O
,	O
sarcopenic	B-I
(	O
SS	B-I
,	O
n	O
=	O
18	O
)	O
,	O
sarcopenic	B-I
obese	I-I
(	O
SO	B-I
,	O
n	O
=	O
29	O
)	O
,	O
and	O
obese	B-I
(	O
OO	B-I
,	O
n	O
=	O
85	O
)	O
phenotypes	O
.	O

Functional	B-O
performance	I-O
was	O
assessed	O
using	O
timed	B-O
up	I-O
and	I-O
go	I-O
,	O
chair	B-O
stand	I-O
,	O
single	B-O
leg	I-O
stand	I-O
,	O
and	O
step	B-O
test	I-O
.	O

Regression	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
medications	O
,	O
and	O
physical	O
activity	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
clinical	O
trial	O
of	O
balance	B-I
-	I-I
based	I-I
torso	I-I
weighting	I-I
for	O
improving	O
upright	O
mobility	O
in	O
people	B-P
with	I-P
multiple	I-P
sclerosis	I-P
.	O

METHODS	O
:	O
This	O
was	O
a	O
2	O
-	O
phase	O
randomized	O
clinical	O
trial	O
.	O

In	O
phase	O
1	O
,	O
36	B-P
participants	I-P
were	O
randomly	O
assigned	O
to	O
experimental	O
and	O
control	O
groups	O
.	O

In	O
phase	O
2	O
,	O
the	O
control	O
group	O
was	O
subsequently	O
randomized	O
into	O
2	O
groups	O
with	O
alternate	B-I
weight	I-I
-	I-I
placement	I-I
.	O

Tests	B-O
of	I-O
upright	I-O
mobility	I-O
included	O
:	O
timed	B-O
up	I-O
and	I-O
go	I-O
(	I-O
TUG	I-O
)	O
,	O
sharpened	B-O
Romberg	I-O
,	O
360	B-O
-	I-O
degree	I-O
turns	I-O
,	O
25	B-O
-	I-O
foot	I-O
walk	I-O
,	O
and	O
computerized	B-O
platform	I-O
posturography	I-O
.	O

Participants	O
were	O
tested	O
at	O
baseline	O
and	O
again	O
with	O
weights	O
placed	O
according	O
to	O
group	O
membership	O
.	O

In	O
both	O
phases	O
,	O
a	O
physical	O
therapist	O
assessed	O
balance	B-O
for	O
the	B-I
BBTW	I-I
group	O
and	O
then	O
placed	O
weights	O
to	O
decrease	O
balance	O
loss	O
.	O

In	O
phase	O
1	O
,	O
the	O
control	O
group	O
had	O
no	B-C
weights	I-C
placed	I-C
.	O

In	O
phase	O
2	O
,	O
the	O
alternate	O
treatment	O
group	O
received	O
standard	B-I
weight	I-I
placement	I-I
of	O
1	O
.	O
5	O
%	O
body	O
weight	O
.	O

-DOCSTART-	O

Title	O
:	O
Lack	O
of	O
efficacy	O
of	O
citalopram	B-I
in	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
and	I-P
high	I-P
levels	I-P
of	I-P
repetitive	I-P
behavior	I-P
:	O
citalopram	B-I
ineffective	O
in	O
children	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
National	O
Institutes	O
of	O
Health	O
-	O
sponsored	O
randomized	O
controlled	O
trial	O
.	O

Six	O
academic	O
centers	O
,	O
including	O
Mount	O
Sinai	O
School	O
of	O
Medicine	O
,	O
North	O
Shore	O
-	O
Long	O
Island	O
Jewish	O
Health	O
System	O
,	O
University	O
of	O
North	O
Carolina	O
at	O
Chapel	O
Hill	O
,	O
University	O
of	O
California	O
at	O
Los	O
Angeles	O
,	O
Yale	O
University	O
,	O
and	O
Dartmouth	O
Medical	O
School	O
.	O

One	B-P
hundred	I-P
forty	I-P
-	I-P
nine	I-P
volunteers	I-P
5	I-P
to	I-P
17	I-P
years	I-P
old	I-P
(	I-P
mean	I-P
[	I-P
SD	I-P
]	I-P
age	I-P
,	I-P
9	I-P
.	I-P
4	I-P
[	I-P
3	I-P
.	I-P
1	I-P
]	I-P
years	I-P
)	I-P
were	O
randomized	O
to	O
receive	O
citalopram	B-I
(	O
n	O
=	O
73	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
76	O
)	O
.	O

Participants	O
had	O
autistic	O
spectrum	O
disorders	O
,	O
Asperger	O
disorder	O
,	O
or	O
pervasive	O
developmental	O
disorder	O
,	O
not	O
otherwise	O
specified	O
;	O
had	O
illness	O
severity	O
ratings	O
of	O
at	O
least	O
moderate	O
on	O
the	B-O
Clinical	I-O
Global	I-O
Impressions	I-O
,	O
Severity	B-O
of	I-O
Illness	I-O
Scale	I-O
;	O
and	O
scored	O
at	O
least	O
moderate	O
on	O
compulsive	O
behaviors	O
measured	O
with	O
the	B-O
Children	I-O
'	I-O
s	I-O
Yale	I-O
-	I-O
Brown	I-O
Obsessive	I-O
Compulsive	I-O
Scales	I-O
modified	O
for	O
pervasive	O
developmental	O
disorders	O
.	O

Twelve	O
weeks	O
of	O
citalopram	B-I
hydrobromide	I-I
(	O
10	O
mg	O
/	O
5	O
mL	O
)	O
or	O
placebo	B-C
.	O

The	O
mean	O
(	O
SD	O
)	O
maximum	O
dosage	O
of	O
citalopram	B-I
hydrobromide	I-I
was	O
16	O
.	O
5	O
(	O
6	O
.	O
5	O
)	O
mg	O
/	O
d	O
by	O
mouth	O
(	O
maximum	O
,	O
20	O
mg	O
/	O
d	O
)	O
.	O

Positive	O
response	O
was	O
defined	O
by	O
a	B-O
score	I-O
of	I-O
much	I-O
improved	I-O
or	O
very	B-O
much	I-O
improved	I-O
on	O
the	B-O
Clinical	I-O
Global	I-O
Impressions	I-O
,	O
Improvement	B-O
subscale	I-O
.	O

An	O
important	O
secondary	O
outcome	O
was	O
the	B-O
score	I-O
on	I-O
the	I-O
Children	I-O
'	I-O
s	I-O
Yale	I-O
-	I-O
Brown	I-O
Obsessive	I-O
Compulsive	I-O
Scales	I-O
modified	I-O
for	I-O
pervasive	I-O
developmental	I-O
disorders	I-O
.	O

Adverse	B-O
events	I-O
were	O
systematically	O
elicited	O
using	O
the	B-O
Safety	I-O
Monitoring	I-O
Uniform	I-O
Report	I-O
Form	I-O
.	O

-DOCSTART-	O

Title	O
:	O
One	O
-	O
year	O
follow	O
-	O
up	O
of	O
the	O
outcome	O
of	O
a	O
randomized	O
controlled	O
trial	O
of	O
a	B-I
home	I-I
-	I-I
based	I-I
intervention	I-I
programme	I-I
for	O
children	B-P
with	I-P
autism	I-P
and	I-P
developmental	I-P
delay	I-P
and	I-P
their	I-P
families	I-P
.	O

METHODS	O
:	O
Randomized	O
controlled	O
trial	O
.	O

Participants	B-P
A	I-P
total	I-P
of	I-P
59	I-P
children	I-P
,	I-P
aged	I-P
3	I-P
-	I-P
5	I-P
years	I-P
,	I-P
attending	I-P
two	I-P
early	I-P
childhood	I-P
intervention	I-P
centres	I-P
in	I-P
Melbourne	I-P
,	I-P
Australia	I-P
.	O

Intervention	O
Half	O
of	O
the	O
subjects	O
received	O
an	B-I
additional	I-I
home	I-I
-	I-I
based	I-I
programme	I-I
consisting	O
of	O
40	O
weekly	O
visits	O
.	O

Bayley	B-O
Scales	I-O
of	I-O
Infant	I-O
Development	I-O
and	O
Wechsler	B-O
Preschool	I-O
and	O
Primary	B-O
Scale	I-O
of	I-O
Intelligence	I-O
Revised	I-O
,	O
Preschool	B-O
Behaviour	I-O
Checklist	I-O
,	O
Bayley	B-O
Behaviour	I-O
Rating	I-O
Scale	I-O
and	O
Behaviour	B-O
Screening	I-O
Questionnaire	I-O
.	O

All	O
tests	O
administered	O
pre	O
-	O
intervention	O
,	O
following	O
the	O
intervention	O
and	O
12	O
months	O
later	O
.	O

Secondary	O
outcome	O
measures	O
Family	B-O
stress	I-O
,	O
support	B-O
and	O
empowerment	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Quick	B-I
change	I-I
versus	O
double	B-I
pump	I-I
while	O
changing	O
the	O
infusion	O
of	O
inotropes	O
:	O
an	O
experimental	O
study	O
.	O

METHODS	O
:	O
The	O
study	O
is	O
a	O
randomized	O
research	O
in	O
an	O
open	O
randomized	O
clinical	O
trial	O
.	O

The	O
study	O
took	O
place	O
at	O
the	O
Paediatric	O
Intensive	O
Care	O
Unit	O
of	O
Padua	O
Hospital	O
.	O

It	O
considered	O
patients	B-P
of	I-P
0	I-P
-	I-P
36	I-P
months	I-P
,	I-P
not	I-P
premature	I-P
,	I-P
treated	I-P
with	I-P
inotropic	I-P
infusion	I-P
with	I-P
monitoring	I-P
of	I-P
blood	I-P
pressure	I-P
.	O

The	O
research	O
obtained	O
the	O
approval	O
of	O
the	O
Hospital	O
Research	O
Ethics	O
committee	O
and	O
parents	O
signed	O
informed	O
consent	O
.	O

Comparison	O
of	O
the	O
two	O
groups	O
made	O
use	O
of	O
the	O
Wilcoxon	O
test	O
for	O
the	O
continuous	O
variables	O
and	O
the	O
Fisher	O
'	O
s	O
exact	O
test	O
for	O
the	O
comparison	O
of	O
frequencies	O
,	O
at	O
significance	O
value	O
of	O
5	O
%	O
.	O

The	O
data	O
were	O
registered	O
in	O
an	O
Excel	O
spreadsheet	O
and	O
analysed	O
with	O
SAS	O
.	O

-DOCSTART-	O

Title	O
:	O
Pharmacokinetic	O
-	O
pharmacodynamic	O
analysis	O
of	O
the	B-I
role	I-I
of	I-I
CYP2C19	I-I
genotypes	I-I
in	I-I
short	I-I
-	I-I
term	I-I
rabeprazole	I-I
-	I-I
based	I-I
triple	I-I
therapy	I-I
against	O
Helicobacter	O
pylori	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
H	I-P
.	I-P
pylori	I-P
infection	I-P
were	O
tested	O
for	O
CYP2C19	O
genotype	O
as	O
poor	O
metabolizers	O
(	O
PMs	O
)	O
or	O
extensive	O
metabolizers	O
(	O
EMs	O
,	O
homozygous	O
EM	O
or	O
heterozygous	O
EM	O
)	O
and	O
given	O
rabeprazole	B-I
for	O
7	O
days	O
.	O

Antibiotics	O
(	O
clarithromycin	O
and	O
amoxicillin	O
)	O
were	O
given	O
on	O
days	O
1	O
-	O
4	O
,	O
days	O
4	O
-	O
7	O
,	O
or	O
days	O
1	O
-	O
7	O
.	O

A	O
direct	O
link	O
model	O
with	O
an	O
effect	O
compartment	O
was	O
used	O
in	O
the	O
population	O
pharmacokinetic	O
-	O
pharmacodynamic	O
analysis	O
.	O

The	B-O
status	I-O
of	I-O
H	I-O
.	I-O
pylori	I-O
infection	I-O
was	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
to	O
evaluate	O
valacyclovir	B-I
alone	I-I
and	O
with	B-I
aspirin	I-I
for	O
asymptomatic	O
HSV	O
-	O
1	O
DNA	O
shedding	O
in	O
human	O
tears	O
and	O
saliva	O
.	O

-DOCSTART-	O

Title	O
:	O
Isometric	B-I
contractions	I-I
reduce	O
plantar	O
flexor	O
moment	O
,	O
Achilles	O
tendon	O
stiffness	O
,	O
and	O
neuromuscular	O
activity	O
but	O
remove	O
the	O
subsequent	O
effects	O
of	O
stretch	O
.	O

METHODS	O
:	O
First	O
,	O
peak	B-O
concentric	I-O
and	O
passive	B-O
ankle	I-O
joint	I-O
moment	I-O
data	I-O
were	O
recorded	O
on	O
an	B-O
isokinetic	I-O
dynamometer	I-O
with	O
electromyographic	O
monitoring	O
of	O
the	O
triceps	O
surae	O
;	O
real	B-O
-	I-O
time	I-O
motion	I-O
analysis	I-O
of	I-O
the	I-O
lower	I-O
leg	I-O
and	O
ultrasound	B-O
imaging	I-O
of	I-O
the	I-O
Achilles	I-O
-	I-O
medial	I-O
gastrocnemius	I-O
muscle	I-O
-	I-O
tendon	I-O
junction	I-O
were	O
simultaneously	O
conducted	O
.	O

Second	O
,	O
the	O
subjects	O
performed	O
six	B-O
8	I-O
-	I-O
s	I-O
maximal	I-O
voluntary	I-O
isometric	I-O
contractions	I-O
(	I-O
MVICs	I-O
)	I-O
before	O
repeating	O
the	O
passive	O
and	O
active	O
trials	O
.	O

METHODS	O
:	O
Third	O
,	O
the	O
subjects	O
performed	O
three	O
60	O
-	O
s	O
static	O
plantar	O
flexor	O
stretches	O
before	O
being	O
retested	O
2	O
and	O
30	O
min	O
after	O
stretch	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
experience	O
of	O
pleasure	O
before	B-I
and	O
after	B-I
hearing	I-I
rehabilitation	I-I
.	O

METHODS	O
:	O
Thirteen	B-P
individuals	I-P
with	I-P
impaired	I-P
hearing	I-P
were	O
tested	O
before	B-I
and	O
after	B-I
6	I-I
months	I-I
of	I-I
hearing	I-I
-	I-I
aid	I-I
use	I-I
,	O
and	O
were	O
compared	O
with	O
19	O
individuals	O
who	O
had	O
worn	O
hearing	B-I
aids	I-I
for	I-I
many	I-I
years	I-I
.	O

The	O
participants	O
reported	O
their	O
daily	B-O
emotional	I-O
experiences	I-O
,	O
by	O
completing	O
questionnaires	B-O
relating	O
to	O
sensory	B-O
and	O
social	B-O
pleasure	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
the	O
effect	O
of	O
intra	B-I
-	I-I
arterial	I-I
versus	O
intravenous	B-I
heparin	I-I
on	O
radial	O
artery	O
occlusion	O
after	O
transradial	O
catheterization	O
.	O

METHODS	O
:	O
We	O
studied	O
500	B-P
consecutive	I-P
patients	I-P
randomized	O
to	O
an	B-I
intravenous	I-I
group	O
(	O
n	O
=	O
250	O
)	O
,	O
receiving	O
50	B-I
U	I-I
/	I-I
kg	I-I
of	I-I
unfractionated	I-I
heparin	I-I
(	O
maximal	O
dose	O
5	O
,	O
000	O
U	O
)	O
intravenously	O
,	O
and	O
an	B-I
intra	I-I
-	I-I
arterial	I-I
group	O
(	O
n	O
=	O
250	O
)	O
receiving	O
the	B-I
same	I-I
dose	I-I
intra	I-I
-	I-I
arterially	I-I
.	O

All	O
patients	O
received	O
a	O
vasodilator	O
"	O
cocktail	O
"	O
intra	O
-	O
arterially	O
and	O
underwent	O
cardiac	O
catheterization	O
using	O
a	O
5F	O
introducer	O
sheath	O
and	O
catheters	O
.	O

The	B-O
activated	I-O
clotting	I-O
time	I-O
was	O
measured	O
at	O
the	O
end	O
of	O
the	O
procedure	O
.	O

All	O
patients	O
received	O
hemostasis	O
with	O
a	O
radial	O
compression	O
device	O
(	O
TR	O
Band	O
)	O
,	O
applied	O
after	O
sheath	O
removal	O
,	O
for	O
2	O
hours	O
.	O

A	B-O
plethysmographic	I-O
evaluation	I-O
for	O
RAO	O
was	O
performed	O
at	O
24	O
hours	O
and	O
30	O
days	O
after	O
the	O
procedure	O
.	O

-DOCSTART-	O

Title	O
:	O
Direct	O
evidence	O
for	O
spinal	B-O
cord	I-O
involvement	I-O
in	O
placebo	B-I
analgesia	I-I
.	O

METHODS	O
:	O
We	O
used	O
functional	B-O
magnetic	I-O
resonance	I-O
imaging	I-O
of	I-O
the	I-O
human	I-O
spinal	I-O
cord	I-O
to	O
test	O
the	O
hypothesis	O
that	B-I
placebo	I-I
analgesia	I-I
results	O
in	O
a	O
reduction	O
of	O
nociceptive	B-O
processing	I-O
in	I-O
the	I-O
spinal	I-O
cord	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
oral	B-I
DMSA	I-I
therapy	I-I
for	O
children	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
:	O
part	O
B	O
-	O
behavioral	O
results	O
.	O

METHODS	O
:	O
Phase	O
1	O
involved	O
65	O
children	O
with	O
ASD	O
who	O
received	O
one	B-I
round	I-I
of	I-I
DMSA	I-I
(	O
3	O
days	O
)	O
.	O

Participants	O
who	O
had	O
high	O
urinary	O
excretion	O
of	O
toxic	O
metals	O
were	O
selected	O
to	O
continue	O
on	O
to	O
phase	O
2	O
.	O

In	O
phase	O
2	O
,	O
49	O
participants	O
were	O
randomly	O
assigned	O
in	O
a	O
double	O
-	O
blind	O
design	O
to	O
receive	O
an	B-I
additional	I-I
6	I-I
rounds	I-I
of	I-I
either	I-I
DMSA	I-I
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Intranasal	B-I
oxytocin	I-I
improves	O
emotion	O
recognition	O
for	O
youth	B-P
with	I-P
autism	I-P
spectrum	I-P
disorders	I-P
.	O

METHODS	O
:	O
In	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
design	O
,	O
we	O
administered	O
oxytocin	B-I
nasal	I-I
spray	I-I
(	O
18	O
or	O
24	O
IU	O
)	O
or	O
a	B-C
placebo	I-C
to	O
16	B-P
male	I-P
youth	I-P
aged	I-P
12	I-P
to	I-P
19	I-P
who	I-P
were	I-P
diagnosed	I-P
with	I-P
Autistic	I-P
or	I-P
Asperger	I-P
'	I-P
s	I-P
Disorder	I-P
.	O

Participants	O
then	O
completed	O
the	B-O
Reading	I-O
the	I-O
Mind	I-O
in	I-O
the	I-O
Eyes	I-O
Task	I-O
,	O
a	B-O
widely	I-O
used	I-O
and	I-O
reliable	I-O
test	I-O
of	I-O
emotion	I-O
recognition	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	O
platelet	O
blockade	O
with	O
cangrelor	B-I
during	O
PCI	O
.	O

METHODS	O
:	O
In	O
this	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
,	O
we	O
randomly	O
assigned	O
5362	B-P
patients	I-P
who	I-P
had	I-P
not	I-P
been	I-P
treated	I-P
with	I-P
clopidogrel	I-P
to	O
receive	O
either	O
cangrelor	B-I
or	O
placebo	B-C
at	O
the	O
time	O
of	O
PCI	O
,	O
followed	O
by	O
600	O
mg	O
of	O
clopidogrel	O
.	O

The	O
primary	O
end	O
point	O
was	O
a	B-O
composite	I-O
of	I-O
death	I-O
,	O
myocardial	B-O
infarction	I-O
,	O
or	O
ischemia	B-O
-	I-O
driven	I-O
revascularization	I-O
at	O
48	O
hours	O
.	O

Enrollment	O
was	O
stopped	O
when	O
an	O
interim	O
analysis	O
concluded	O
that	O
the	O
trial	O
would	O
be	O
unlikely	O
to	O
show	O
superiority	O
for	O
the	O
primary	O
end	O
point	O
.	O

-DOCSTART-	O

Title	O
:	O
Low	B-I
-	I-I
frequency	I-I
repetitive	I-I
transcranial	I-I
magnetic	I-I
stimulation	I-I
(	I-I
rTMS	I-I
)	I-I
affects	O
event	O
-	O
related	O
potential	O
measures	O
of	O
novelty	O
processing	O
in	O
autism	O
.	O

METHODS	O
:	O
Our	O
hypothesis	O
was	O
that	O
low	B-I
-	I-I
frequency	I-I
rTMS	I-I
application	O
to	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLFPC	O
)	O
would	O
result	O
in	O
an	B-O
alteration	I-O
of	I-O
the	I-O
cortical	I-O
excitatory	I-O
/	I-O
inhibitory	I-O
balance	I-O
through	O
the	O
activation	O
of	O
inhibitory	O
GABAergic	O
double	O
bouquet	O
interneurons	O
.	O

We	O
expected	O
to	O
find	O
post	O
-	O
TMS	O
differences	O
in	O
amplitude	B-O
and	O
latency	B-O
of	I-O
early	I-O
and	O
late	B-O
ERP	I-O
components	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
efficacy	O
of	O
melatonin	B-I
for	I-I
sleep	I-I
problems	I-I
in	O
children	B-P
with	I-P
autism	I-P
,	I-P
fragile	I-P
X	I-P
syndrome	I-P
,	I-P
or	I-P
autism	I-P
and	I-P
fragile	I-P
X	I-P
syndrome	I-P
.	O

METHODS	O
:	O
A	O
4	O
-	O
week	O
,	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
crossover	O
design	O
was	O
conducted	O
following	O
a	O
1	O
-	O
week	O
baseline	O
period	O
.	O

Either	O
melatonin	B-I
,	O
3	O
mg	O
,	O
or	O
placebo	B-C
was	O
given	O
to	O
participants	O
for	O
2	O
weeks	O
and	O
then	O
alternated	O
for	O
another	O
2	O
weeks	O
.	O

Sleep	O
variables	O
,	O
including	O
sleep	B-O
duration	I-O
,	O
sleep	B-O
-	I-O
onset	I-O
time	I-O
,	O
sleep	B-O
-	I-O
onset	I-O
latency	I-O
time	I-O
,	O
and	O
the	B-O
number	I-O
of	I-O
night	I-O
awakenings	I-O
,	O
were	O
recorded	O
using	O
an	B-O
Actiwatch	I-O
and	O
from	O
sleep	B-O
diaries	I-O
completed	O
by	O
parents	O
.	O

All	O
participants	O
had	O
been	O
thoroughly	O
assessed	O
for	O
ASD	O
and	O
also	O
had	O
DNA	O
testing	O
for	O
the	O
diagnosis	O
of	O
FXS	O
.	O

-DOCSTART-	O

Title	O
:	O
Body	B-I
size	I-I
indexes	I-I
for	I-I
optimizing	I-I
iodine	I-I
dose	I-I
for	O
aortic	O
and	O
hepatic	O
enhancement	O
at	O
multidetector	O
CT	O
:	O
comparison	O
of	O
total	O
body	O
weight	O
,	O
lean	O
body	O
weight	O
,	O
and	O
blood	O
volume	O
.	O

METHODS	O
:	O
Institutional	O
review	O
committee	O
approval	O
and	O
written	O
informed	O
consent	O
were	O
obtained	O
.	O

One	B-P
hundred	I-P
twenty	I-P
patients	I-P
(	I-P
54	I-P
men	I-P
,	I-P
66	I-P
women	I-P
;	I-P
mean	I-P
age	I-P
,	I-P
64	I-P
.	I-P
1	I-P
years	I-P
;	I-P
range	I-P
,	I-P
19	I-P
-	I-P
88	I-P
years	I-P
)	I-P
who	I-P
underwent	I-P
multidetector	I-P
CT	I-P
of	I-P
the	I-P
upper	I-P
abdomen	I-P
were	O
randomized	O
into	O
three	O
groups	O
of	O
40	O
patients	O
each	O
:	O
(	O
a	O
)	O
TBW	B-I
group	O
(	O
0	B-I
.	I-I
6	I-I
g	I-I
of	I-I
iodine	I-I
per	I-I
kilogram	I-I
of	I-I
TBW	I-I
)	O
,	O
(	O
b	O
)	O
LBW	B-I
group	O
(	O
0	B-I
.	I-I
821	I-I
g	I-I
of	I-I
iodine	I-I
per	I-I
kilogram	I-I
of	I-I
LBW	I-I
)	O
,	O
and	O
(	O
c	O
)	O
BV	B-I
group	O
(	O
men	O
,	O
8	B-I
.	I-I
6	I-I
g	I-I
of	I-I
iodine	I-I
per	I-I
liter	I-I
of	I-I
BV	I-I
;	O
women	O
,	O
9	B-I
.	I-I
9	I-I
g	I-I
of	I-I
iodine	I-I
per	I-I
liter	I-I
of	I-I
BV	I-I
)	O
.	O

Change	O
in	O
CT	B-O
number	I-O
between	I-O
unenhanced	I-O
and	I-O
contrast	I-O
-	I-O
enhanced	I-O
images	I-O
per	I-O
gram	I-O
of	I-O
iodine	I-O
and	O
maximum	B-O
hepatic	I-O
enhancement	I-O
(	I-O
MHE	I-O
)	I-O
adjusted	O
for	O
iodine	O
dose	O
were	O
examined	O
for	O
correlation	O
with	O
TBW	B-I
,	O
LBW	B-I
,	O
and	O
BV	B-I
by	O
using	O
linear	O
regression	O
analysis	O
.	O

-DOCSTART-	O

Title	O
:	O
Acupuncture	B-I
versus	O
venlafaxine	B-I
for	O
the	O
management	O
of	O
vasomotor	O
symptoms	O
in	O
patients	B-P
with	I-P
hormone	I-P
receptor	I-P
-	I-P
positive	I-P
breast	I-P
cancer	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Fifty	B-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
12	B-I
weeks	I-I
of	I-I
acupuncture	I-I
(	O
n	O
=	O
25	O
)	O
or	O
venlafaxine	B-I
(	O
n	O
=	O
25	O
)	O
treatment	O
.	O

Health	B-O
outcomes	I-O
were	O
measured	O
for	O
up	O
to	O
1	O
year	O
post	O
-	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Gluten	B-I
-	I-I
free	I-I
diet	I-I
in	O
infantile	O
autism	O
.	O

A	O
therapeutic	O
trial	O
]	O
.	O

METHODS	O
:	O
In	O
this	O
study	O
seven	B-P
patients	I-P
with	I-P
infantile	I-P
autism	I-P
,	I-P
three	I-P
before	I-P
puberty	I-P
and	I-P
four	I-P
after	I-P
puberty	I-P
,	O
were	O
given	O
a	B-I
gluten	I-I
-	I-I
free	I-I
diet	I-I
.	O

Three	O
children	O
were	O
provoked	O
with	O
gluten	B-I
/	O
placebo	B-C
in	O
a	O
double	O
-	O
blind	O
study	O
.	O

Four	O
young	O
patients	O
participated	O
in	O
an	O
open	O
study	O
and	O
were	O
given	O
a	B-I
gluten	I-I
-	I-I
free	I-I
diet	I-I
in	O
six	O
months	O
.	O

Behaviour	B-O
was	O
registered	O
before	O
,	O
during	O
and	O
after	O
the	O
period	O
with	O
a	B-I
gluten	I-I
-	I-I
free	I-I
diet	I-I
.	O

Visual	B-O
Analogue	I-O
Scale	I-O
and	O
Real	B-O
Life	I-O
Rating	I-O
Scale	I-O
were	O
used	O
to	O
register	O
changes	O
in	O
behaviour	B-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
clinical	O
trial	O
of	O
the	O
efficacy	O
of	O
scheduled	B-I
dosing	I-I
of	I-I
acetaminophen	I-I
and	O
hydrocodone	B-I
for	O
the	O
management	O
of	O
postoperative	O
pain	O
in	O
children	B-P
after	I-P
tonsillectomy	I-P
.	O

METHODS	O
:	O
Children	B-P
6	I-P
to	I-P
15	I-P
years	I-P
of	I-P
age	I-P
were	O
randomized	O
to	O
receive	O
acetaminophen	B-I
and	O
hydrocodone	B-I
(	O
167	O
mg	O
/	O
2	O
.	O
5	O
mg	O
/	O
5	O
mL	O
)	O
for	O
3	O
days	O
after	O
surgery	O
:	O
Group	O
A	O
(	O
N=39	O
)	O
-	O
every	B-I
4	I-I
hours	I-I
PRN	I-I
,	O
with	O
standard	O
postoperative	O
instructions	O
;	O
Group	O
B	O
(	O
N=34	O
)	O
-	O
every	B-I
4	I-I
hours	I-I
ATC	I-I
,	O
with	O
standard	O
postoperative	O
instructions	O
,	O
without	O
nurse	O
coaching	O
;	O
and	O
Group	O
C	O
(	O
N=40	O
)	O
-	O
every	B-I
4	I-I
hours	I-I
ATC	I-I
,	O
with	O
standard	O
postoperative	O
instructions	O
,	O
with	O
coaching	O
.	O

Parents	O
completed	O
a	B-O
medication	I-O
log	I-O
,	O
and	O
recorded	B-O
the	I-O
presence	I-O
and	O
severity	B-O
of	I-O
opioid	I-O
-	I-O
related	I-O
adverse	I-O
effects	I-O
and	O
children	B-O
'	I-O
s	I-O
reports	I-O
of	I-O
pain	I-O
intensity	I-O
using	O
a	B-O
0	I-O
to	I-O
10	I-O
numeric	I-O
rating	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Prophylactic	B-I
amnioinfusion	I-I
in	O
pregnancies	O
complicated	O
by	O
oligohydramnios	O
:	O
a	O
prospective	O
study	O
.	O

METHODS	O
:	O
Subjects	O
were	O
randomly	O
assigned	O
to	O
one	O
of	O
three	O
groups	O
:	O
amnioinfusion	B-I
with	I-I
warmed	I-I
saline	I-I
solution	I-I
,	O
room	B-I
-	I-I
temperature	I-I
saline	I-I
,	O
or	O
control	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
controlled	O
caregiver	B-I
mediated	I-I
joint	I-I
engagement	I-I
intervention	I-I
for	O
toddlers	B-P
with	I-P
autism	I-P
.	O

METHODS	O
:	O
The	O
intervention	O
consisted	O
of	O
24	B-I
caregiver	I-I
-	I-I
mediated	I-I
sessions	I-I
with	O
follow	O
-	O
up	O
1	O
year	O
later	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
membrane	B-I
permeability	I-I
on	O
inflammation	O
and	O
arterial	O
stiffness	O
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
Stable	B-P
patients	I-P
who	I-P
had	I-P
anuria	I-P
and	I-P
were	I-P
on	I-P
low	I-P
-	I-P
flux	I-P
polysulfone	I-P
membrane	I-P
were	O
randomly	O
allocated	O
either	O
to	O
HD	B-I
with	I-I
high	I-I
-	I-I
flux	I-I
polyamide	I-I
membrane	I-I
(	O
group	O
A	O
;	O
22	O
patients	O
)	O
or	O
to	O
HD	B-I
with	I-I
low	I-I
-	I-I
flux	I-I
polyamide	I-I
membrane	I-I
(	O
group	O
B	O
;	O
24	O
patients	O
)	O
for	O
24	O
weeks	O
,	O
then	O
they	O
were	O
started	O
on	O
24	O
weeks	O
of	O
the	O
alternative	O
HD	O
treatment	O
.	O

Apart	O
from	O
the	O
dialyzer	O
,	O
the	O
dialysis	O
prescription	O
remained	O
unchanged	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
prospective	O
multicenter	O
randomized	O
comparative	O
study	O
between	O
the	B-I
U	I-I
-	I-I
and	O
H	B-I
-	I-I
type	I-I
methods	I-I
of	I-I
the	I-I
TVT	I-I
SECUR	I-I
procedure	I-I
for	O
the	O
treatment	O
of	O
female	B-P
stress	I-P
urinary	I-P
incontinence	I-P
:	O
1	O
-	O
year	O
follow	O
-	O
up	O
.	O

METHODS	O
:	O
Women	B-P
with	I-P
urodynamic	I-P
SUI	I-P
were	O
enrolled	O
in	O
this	O
12	O
-	O
mo	O
multicenter	O
randomized	O
study	O
.	O

Subjects	O
were	O
randomly	O
allocated	O
to	O
either	O
the	B-I
U	I-I
-	I-I
or	O
H	B-I
-	I-I
type	I-I
method	I-I
of	I-I
TVT	I-I
-	I-I
S	I-I
.	O

Pre	O
-	O
and	O
postoperative	O
evaluations	O
included	O
a	B-O
standing	I-O
stress	I-O
test	I-O
,	O
the	B-O
Sandvik	I-O
questionnaire	I-O
,	O
the	B-O
Incontinence	I-O
Quality	I-O
of	I-O
Life	I-O
(	I-O
I	I-O
-	I-O
QOL	I-O
)	I-O
questionnaire	I-O
,	O
and	O
the	B-O
International	I-O
Consultation	I-O
on	I-O
Incontinence	I-O
Questionnaire	I-O
-	I-O
Female	I-O
Lower	I-O
Urinary	I-O
Tract	I-O
Symptoms	I-O
(	I-O
ICIQ	I-O
-	I-O
FLUTS	I-O
)	I-O
.	O

Patients	B-O
'	I-O
satisfaction	I-O
and	O
complications	B-O
were	O
evaluated	O
.	O

Objective	O
and	O
subjective	O
cures	O
were	O
defined	O
as	O
no	B-O
leakage	I-O
on	I-O
the	I-O
stress	I-O
test	I-O
and	O
responses	B-O
on	I-O
the	I-O
Sandvik	I-O
questionnaire	I-O
,	O
respectively	O
.	O

We	O
compared	O
the	O
surgical	O
outcomes	O
between	O
the	O
two	O
methods	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
two	B-I
different	I-I
testosterone	I-I
undecanoate	I-I
formulations	I-I
in	O
hypogonadal	B-P
men	I-P
with	I-P
metabolic	I-P
syndrome	I-P
.	O

METHODS	O
:	O
Randomized	O
,	O
double	O
-	O
blind	O
,	O
double	O
-	O
dummy	O
study	O
with	O
three	O
parallel	O
treatment	O
arms	O
[	O
oral	B-I
TU	I-I
;	O
transdermal	B-C
placebo	I-C
gel	I-C
(	I-C
P	I-C
)	I-C
;	O
im	B-I
TU	I-I
]	O
administration	O
for	O
12	O
months	O
(	O
mo	O
)	O
.	O

Each	O
subject	O
was	O
randomized	O
(	O
1:1:3	O
)	O
to	O
receive	O
either	O
oral	B-I
TU	I-I
(	O
2	O
capsules	O
of	O
40	O
mg	O
/	O
twice	O
per	O
day	O
at	O
breakfast	O
and	O
dinner	O
,	O
equalling	O
a	O
total	O
dose	O
of	O
160	O
mg	O
/	O
day	O
;	O
no	O
.	O
=10	O
)	O
for	O
6	O
mo	O
and	O
continued	O
with	O
im	B-I
TU	I-I
for	O
further	O
6	O
mo	O
,	O
or	O
P	O
(	O
3	O
-	O
4	O
g	O
/	O
day	O
;	O
no	O
.	O
=10	O
)	O
and	O
im	B-I
TU	I-I
(	O
1000	O
mg	O
/	O
12	O
weeks	O
from	O
week	O
6	O
;	O
no	O
.	O
=32	O
)	O
for	O
12	O
mo	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
unconscious	O
thought	O
effect	O
in	O
clinical	O
decision	O
making	O
:	O
an	O
example	O
in	O
diagnosis	O
.	O

METHODS	O
:	O
They	O
used	O
case	O
descriptions	O
from	O
the	O
DSM	O
-	O
IV	O
casebook	O
.	O

Half	O
of	O
the	O
participants	O
were	O
randomly	O
assigned	O
to	O
the	B-I
conscious	I-I
-	I-I
processing	I-I
-	I-I
condition	I-I
(	O
i	O
.	O
e	O
.	O
,	O
consciously	O
thinking	O
about	O
the	O
information	O
they	O
read	O
in	O
the	O
case	O
description	O
)	O
,	O
the	O
other	O
half	O
to	O
the	B-I
unconscious	I-I
-	I-I
processing	I-I
condition	I-I
(	O
i	O
.	O
e	O
.	O
,	O
performing	O
an	O
unrelated	O
distracter	O
task	O
)	O
.	O

The	O
main	O
dependent	O
measure	O
was	O
the	B-O
total	I-O
number	I-O
of	I-O
correct	I-O
classifications	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Metformin	B-I
,	O
naltrexone	B-I
,	O
or	O
the	O
combination	O
of	O
prednisolone	B-I
and	O
antiandrogenic	B-I
oral	I-I
contraceptives	I-I
as	O
first	O
-	O
line	O
therapy	O
in	O
hyperinsulinemic	B-P
women	I-P
with	I-P
polycystic	I-P
ovary	I-P
syndrome	I-P
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
prophylactic	B-I
fentanyl	I-I
on	O
shivering	O
in	O
elective	O
caesarean	O
section	O
under	O
epidural	O
analgesia	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
controlled	O
trial	O
of	O
the	B-I
focus	I-I
parent	I-I
training	I-I
for	O
toddlers	B-P
with	I-P
autism	I-P
:	O
1	O
-	O
year	O
outcome	O
.	O

METHODS	O
:	O
Seventy	B-P
-	I-P
five	I-P
toddlers	I-P
with	I-P
autism	I-P
spectrum	I-P
disorder	I-P
(	I-P
65	I-P
autism	I-P
,	I-P
10	I-P
PDD	I-P
-	I-P
NOS	I-P
,	I-P
mean	I-P
age	I-P
=	I-P
34	I-P
.	I-P
4	I-P
months	I-P
,	I-P
SD	I-P
=	I-P
6	I-P
.	I-P
2	I-P
)	I-P
were	O
enrolled	O
.	O

Analyses	O
were	O
conducted	O
on	O
a	O
final	O
sample	O
of	O
67	O
children	O
(	O
lost	O
to	O
follow	O
-	O
up	O
=	O
8	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Acute	O
and	O
late	O
toxicity	O
in	O
a	O
randomized	O
trial	O
of	O
conventional	B-C
versus	O
hypofractionated	B-I
three	I-I
-	I-I
dimensional	I-I
conformal	I-I
radiotherapy	I-I
for	O
prostate	O
cancer	O
.	O

METHODS	O
:	O
Between	O
January	O
2003	O
and	O
December	O
2007	O
,	O
168	B-P
patients	I-P
were	O
randomized	O
to	O
receive	O
either	O
hypofractionated	B-I
(	O
62	O
Gy	O
in	O
20	O
fractions	O
within	O
5	O
weeks	O
,	O
4	O
fractions	O
/	O
wk	O
)	O
or	O
conventionally	B-C
fractionated	I-C
(	I-C
80	I-C
Gy	I-C
in	I-C
40	I-C
fractions	I-C
within	I-C
8	I-C
weeks	I-C
)	I-C
three	I-C
-	I-C
dimensional	I-C
conformal	I-C
radiotherapy	I-C
to	O
the	O
prostate	O
and	O
seminal	O
vesicles	O
.	O

All	O
patients	O
had	O
undergone	O
a	O
9	O
-	O
month	O
course	O
of	O
total	O
androgen	O
deprivation	O
,	O
with	O
radiotherapy	B-I
starting	O
2	O
months	O
after	O
initiation	O
of	O
the	O
total	O
androgen	O
deprivation	O
.	O

-DOCSTART-	O

Title	O
:	O
Vinegar	B-I
intake	I-I
enhances	O
flow	O
-	O
mediated	O
vasodilatation	O
via	O
upregulation	O
of	O
endothelial	O
nitric	O
oxide	O
synthase	O
activity	O
.	O

-DOCSTART-	O

Title	O
:	O
Early	O
withdrawal	O
of	O
calcineurin	B-I
inhibitors	I-I
and	O
everolimus	B-I
monotherapy	I-I
in	O
de	B-P
novo	I-P
liver	I-P
transplant	I-P
recipients	I-P
preserves	I-P
renal	I-P
function	I-P
.	O

METHODS	O
:	O
All	O
patients	O
were	O
treated	O
with	O
CsA	B-I
for	O
the	O
first	O
10	O
days	O
and	O
then	O
randomized	O
to	O
receive	O
Evr	B-I
in	O
combination	O
with	O
CsA	B-I
up	O
to	O
day	O
30	O
,	O
then	O
either	O
continued	O
on	O
Evr	B-I
monotherapy	I-I
(	O
Evr	B-I
group	O
)	O
or	O
maintained	O
on	O
CsA	B-I
with	I-I
/	O
without	B-I
mycophenolate	I-I
mofetil	I-I
(	O
CsA	B-I
group	O
)	O
in	O
case	O
of	O
chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
de	B-I
novo	I-I
or	O
early	B-I
everolimus	I-I
with	I-I
low	I-I
cyclosporine	I-I
in	O
deceased	B-P
-	I-P
donor	I-P
kidney	I-P
transplant	I-P
recipients	I-P
at	I-P
specified	I-P
risk	I-P
of	I-P
delayed	I-P
graft	I-P
function	I-P
:	O
12	O
-	O
month	O
results	O
of	O
a	O
randomized	O
,	O
multicenter	O
trial	O
.	O

METHODS	O
:	O
CALLISTO	O
was	O
a	O
12	O
-	O
month	O
,	O
prospective	O
,	O
multicenter	O
,	O
open	O
-	O
label	O
study	O
.	B-P

Deceased	I-P
-	I-P
donor	I-P
kidney	I-P
transplant	I-P
patients	I-P
at	I-P
protocol	I-P
-	I-P
specified	I-P
risk	I-P
of	I-P
DGF	I-P
were	O
randomized	O
to	O
start	O
everolimus	B-I
on	O
day	O
1	O
(	O
immediate	B-I
everolimus	I-I
,	O
IE	B-I
;	O
n	O
=	O
65	O
)	O
or	O
week	O
5	O
(	O
delayed	B-I
everolimus	I-I
,	O
DE	B-I
;	O
n	O
=	O
74	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
leisure	I-I
programme	I-I
on	O
quality	O
of	O
life	O
and	O
stress	O
of	O
individuals	B-P
with	I-P
ASD	I-P
.	O

METHODS	O
:	O
Therefore	O
,	O
a	O
study	O
using	O
a	O
repeated	O
measures	O
design	O
was	O
used	O
to	O
measure	O
effects	O
of	O
a	B-I
1	I-I
-	I-I
year	I-I
group	I-I
leisure	I-I
programme	I-I
intended	O
to	O
facilitate	O
interaction	B-I
with	I-I
media	I-I
,	O
engagement	B-I
in	I-I
exercise	I-I
,	O
playing	B-I
games	I-I
and	O
doing	B-I
crafts	I-I
,	O
attending	B-I
events	I-I
,	O
and	O
participating	B-I
in	I-I
other	I-I
recreation	I-I
activities	I-I
on	O
quality	B-O
of	I-O
life	I-O
and	O
stress	B-O
of	O
37	O
participants	O
(	O
22	O
male	O
,	O
15	O
female	O
)	O
,	O
ages	O
17	O
-	O
39	O
(	O
M	O
=	O
31	O
.	O
49	O
)	O
years	O
at	O
the	O
beginning	O
of	O
the	O
programme	O
)	O
diagnosed	O
with	O
an	O
ASD	O
and	O
a	O
group	O
of	O
34	O
adults	O
with	O
ASD	O
as	O
control	O
group	O

(	O
waiting	O
list	O
)	O
(	O
19	O
male	O
,	O
15	O
female	O
)	O
,	O
ages	O
24	O
-	O
38	O
(	O
M	O
=	O
30	O
at	O
programme	O
initiation	O
)	O
years	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
cognitive	B-I
behavioral	I-I
therapy	I-I
on	O
daily	O
living	O
skills	O
in	O
children	B-P
with	I-P
high	I-P
-	I-P
functioning	I-P
autism	I-P
and	I-P
concurrent	I-P
anxiety	I-P
disorders	I-P
.	O

METHODS	O
:	O
Forty	B-P
children	I-P
with	I-P
ASD	I-P
(	I-P
7	I-P
-	I-P
11	I-P
years	I-P
)	I-P
and	I-P
their	I-P
primary	I-P
caregiver	I-P
were	O
randomly	O
assigned	O
to	O
an	B-I
immediate	I-I
treatment	I-I
(	O
IT	B-I
;	O
n	O
=	O
17	O
)	O
or	O
3	B-C
-	I-C
month	I-C
waitlist	I-C
(	O
WL	B-C
;	O
n	O
=	O
23	O
)	O
condition	O
.	O

-DOCSTART-	O

Title	O
:	O
Ventilator	B-I
-	I-I
delivered	I-I
mask	I-I
ventilation	I-I
compared	O
with	O
three	B-C
standard	I-C
methods	I-C
of	I-C
mask	I-C
ventilation	I-C
in	O
a	O
manikin	O
model	O
.	O

METHODS	O
:	O
A	O
modified	O
resuscitation	O
manikin	O
was	O
used	O
to	O
measure	O
variation	O
in	O
mechanical	O
ventilation	O
during	O
3	O
-	O
min	O
periods	O
of	O
mask	O
ventilation	O
.	O

Thirty	B-P
-	I-P
six	I-P
experienced	I-P
practitioners	I-P
gave	O
positive	O
pressure	O
mask	O
ventilation	O
targeting	O
acceptable	O
chest	O
wall	O
movement	O
with	O
a	O
rate	O
of	O
60	O
inflations	O
/	O
min	O
and	O
when	O
pressures	O
could	O
be	O
targeted	O
or	O
set	O
,	O
a	O
peak	O
inspiratory	O
pressure	O
(	O
PIP	O
)	O
of	O
18	O
cm	O
water	O
,	O
positive	O
end	O
-	O
expiratory	O
pressure	O
(	O
PEEP	O
)	O
of	O
5	O
cm	O
water	O
,	O
for	O
3	O
min	O
with	O
each	O
of	O
the	O
four	O
mask	O
ventilation	O
methods	O
.	O

Each	O
mode	O
was	O
randomly	O
sequenced	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
multicenter	O
,	O
open	O
-	O
label	O
study	O
of	O
vernakalant	B-I
for	O
the	O
conversion	O
of	O
atrial	O
fibrillation	O
to	O
sinus	O
rhythm	O
.	O

METHODS	O
:	O
Adult	B-P
patients	I-P
with	I-P
AF	I-P
and	I-P
an	I-P
indication	I-P
for	I-P
conversion	I-P
to	I-P
SR	I-P
received	O
a	B-I
10	I-I
-	I-I
minute	I-I
intravenous	I-I
infusion	I-I
of	I-I
vernakalant	I-I
(	O
3	O
mg	O
/	O
kg	O
)	O
.	O

If	O
after	O
a	O
15	O
-	O
minute	O
observation	O
period	O
AF	O
was	O
present	O
,	O
a	B-I
second	I-I
10	I-I
-	I-I
minute	I-I
infusion	I-I
of	I-I
intravenous	I-I
vernakalant	I-I
(	O
2	O
mg	O
/	O
kg	O
)	O
was	O
given	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
was	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
with	I-O
recent	I-O
-	I-O
onset	I-O
AF	I-O
(	O
AF	O
lasting	O
>	O
3	O
hours	O
to	O
<	O
or	O
=7	O
days	O
)	O
who	O
converted	O
to	O
SR	O
within	O
90	O
minutes	O
of	O
the	O
start	O
of	O
the	O
first	O
infusion	O
.	O

Safety	B-O
evaluations	I-O
included	O
vital	B-O
signs	I-O
,	O
telemetry	B-O
and	O
Holter	B-O
monitoring	I-O
,	O
12	B-O
-	I-O
lead	I-O
electrocardiography	I-O
,	O
clinical	B-O
laboratory	I-O
tests	I-O
,	O
physical	B-O
examinations	I-O
,	O
and	O
adverse	B-O
events	I-O
(	I-O
AEs	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
explicit	B-I
instruction	I-I
on	O
Japanese	O
Verbal	O
Learning	O
Test	O
in	O
schizophrenia	B-P
patients	I-P
.	O

METHODS	O
:	O
After	O
random	O
assignment	O
of	O
20	B-P
schizophrenia	I-P
patients	I-P
to	O
either	O
an	B-I
explicit	I-I
or	O
normal	B-C
instruction	I-C
group	O
,	O
the	B-O
Japanese	I-O
Verbal	I-O
Learning	I-O
Test	I-O
was	O
administered	O
to	O
them	O
.	O

-DOCSTART-	O

Title	O
:	O
Tensile	O
bond	O
strength	O
of	O
a	O
lithium	O
-	O
disilicate	O
pressed	O
glass	O
ceramic	O
to	O
dentin	B-I
of	I-I
different	I-I
surface	I-I
treatments	I-I
.	O

METHODS	O
:	O
Sixty	O
7x3	O
mm	O
pressed	O
ceramic	O
discs	O
of	O
IPS	O
e	O
.	O
max	O
were	O
fabricated	O
and	O
randomly	O
assigned	O
to	O
six	O
groups	O
of	O
different	B-I
dentin	I-I
surface	I-I
treatments	I-I
(	O
control	O
,	O
desensitizer	B-I
,	O
disinfectant	B-I
,	O
saliva	B-I
,	O
blood	B-I
,	O
and	O
hydrogen	B-I
peroxide	I-I
)	O
.	O

Representative	O
samples	O
of	O
fractured	O
specimens	O
were	O
observed	O
by	O
SEM	B-O
(	I-O
scanning	I-O
electron	I-O
microscopy	I-O
)	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
comparison	O
of	O
the	O
effect	O
of	O
short	B-I
-	I-I
term	I-I
aromatase	I-I
inhibitor	I-I
(	O
letrozole	B-I
)	O
and	O
GnRH	B-I
agonist	I-I
(	O
triptorelin	B-I
)	O
versus	O
case	O
control	O
on	O
pregnancy	O
rate	O
and	O
symptom	O
and	O
sign	O
recurrence	O
after	O
laparoscopic	O
treatment	O
of	O
endometriosis	O
.	O

METHODS	O
:	O
In	O
a	O
prospective	O
randomized	O
clinical	O
trial	O
,	O
after	O
treatment	O
of	O
144	B-P
infertile	I-P
women	I-P
in	I-P
their	I-P
reproductive	I-P
age	I-P
by	I-P
laparoscopy	I-P
(	I-P
whose	I-P
endometriosis	I-P
was	I-P
confirmed	I-P
by	I-P
prior	I-P
laparoscopy	I-P
)	I-P
,	O
they	O
were	O
divided	O
into	O
3	O
groups	O
:	O
group	O
1	O
(	O
47	O
cases	O
)	O
who	O
received	O
letrozole	B-I
for	O
2	O
months	O
,	O
group	O
2	O
(	O
40	O
patients	O
)	O
who	O
were	O
prescribed	O
triptorelin	B-I
for	O
2	O
months	O
and	O
group	O
3	O
who	O
were	O
57	O
patients	O
in	O
the	O
control	O
group	O
and	O
did	O
not	B-C
receive	I-C
any	I-C
medication	I-C
.	O

We	O
followed	O
up	O
each	O
group	O
at	O
least	O
for	O
12	O
months	O
after	O
their	O
restoration	O
of	O
regular	O
cycle	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Therapy	O
with	O
alpha	B-I
-	I-I
interferon	I-I
in	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
with	O
a	O
low	O
grade	O
of	O
malignancy	O
(	O
correct	O
title	O
supplied	O
from	O
Table	O
of	O
Contents	O
)	O
]	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
phase	O
II	O
randomized	O
trial	O
comparing	O
radiotherapy	O
with	O
concurrent	B-I
weekly	I-I
cisplatin	I-I
or	O
weekly	B-I
paclitaxel	I-I
in	O
patients	B-P
with	I-P
advanced	I-P
cervical	I-P
cancer	I-P
.	O

METHODS	O
:	O
Between	O
May	O
2000	O
and	O
May	O
2004	O
,	O
31	B-P
women	I-P
with	I-P
FIGO	I-P
stage	I-P
IB2	I-P
-	I-P
IVA	I-P
cervical	I-P
cancer	I-P
or	I-P
with	I-P
postsurgical	I-P
pelvic	I-P
recurrence	I-P
were	O
enrolled	O
into	O
this	O
phase	O
II	O
study	O
and	O
randomized	O
to	O
receive	O
on	O
a	O
weekly	O
basis	O
either	O
40	B-I
mg	I-I
/	I-I
m	I-I
Cisplatin	I-I
(	O
group	O
I	O
;	O
16	O
patients	O
)	O
or	O
50	B-I
mg	I-I
/	I-I
m	I-I
paclitaxel	I-I
(	O
group	O
II	O
;	O
15	O
patients	O
)	O
concurrently	O
with	O
radiotherapy	O
.	O

Median	O
total	O
dose	O
to	O
point	O
A	O
was	O
74	O
Gy	O
(	O
range	O
:	O
66	O
-	O
92	O
Gy	O
)	O
for	O
group	O
I	O
and	O
66	O
Gy	O
(	O
range	O
:	O
40	O
-	O
98	O
Gy	O
)	O
for	O
group	O
II	O
.	O

Median	O
follow	O
-	O
up	O
time	O
was	O
46	O
months	O
.	O

